Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial-Reference-Cited by-同舟云学术

Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial

Published:2020-03 Issue:3 Volume:7 Page:e164-e172
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Schürmann Dirk,Rudd Deanne Jackson,Zhang Saijuan,De Lepeleire Inge,Robberechts Martine,Friedman Evan,Keicher Christian,Hüser Andreas,Hofmann Jörg,Grobler Jay A,Stoch S Aubrey,Iwamoto Marian,Matthews Randolph P

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference23 articles.

1. The end of AIDS: HIV infection as a chronic disease;Deeks;Lancet,2013

2. The role of adherence to antiretroviral therapy in the management of HIV infection;Conway;J Acquir Immune Defic Syndr,2007

3. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV;Cohen;BMJ Open,2013

4. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials;Nachega;Clin Infect Dis,2014

5. Current status and prospects of HIV treatment;Cihlar;Curr Opin Virol,2016

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intracellular islatravir-triphosphate half-life supports extended dosing intervals;Antimicrobial Agents and Chemotherapy;2024-09-04

2. The Current Pipeline of Antiretroviral Therapy;Infectious Disease Clinics of North America;2024-09

3. Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant;CPT: Pharmacometrics & Systems Pharmacology;2024-08-20

4. Thorough QT/QTc study to evaluate the effect of a single supratherapeutic dose of islatravir on QTc interval prolongation in healthy adults;Antimicrobial Agents and Chemotherapy;2024-08-07

5. Challenges for Novel Antiretroviral Development in an Era of Widespread tenofovir-disoproxil/lamivudine (or emtricitabine)/dolutegravir availability (TLD) Availability;Clinical Infectious Diseases;2024-07-11